This website uses cookies.

By clicking the "Accept" button or continuing to browse our site, you agree to first-party and session-only cookies being stored on your device to enhance site navigation and analyze site performance and traffic. For more information on our use of cookies, please see our Privacy Policy.

The AEA website will be offline for brief scheduled maintenance after 6:00pm (EDT) this evening.
  1. Home
  2. Journals
  3. American Economic Review
  4. March 2024
  5. The Economics of the Public Option: Evidence from Local Pharmaceutical Markets

The Economics of the Public Option: Evidence from Local Pharmaceutical Markets

  • Juan Pablo Atal
  • José Ignacio Cuesta
  • Felipe González
  • Cristóbal Otero
American Economic Review
vol. 114, no. 3, March 2024
(pp. 615-44)
Download Full Text PDF
(Complimentary)

Abstract

We study the effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile. Public pharmacies sell the same drugs at a third of private pharmacy prices, because of stronger upstream bargaining and market power in the private sector, but are of lower quality. Public pharmacies induced market segmentation and price increases in the private sector, which benefited the switchers to the public option but harmed the stayers. The countrywide entry of public pharmacies would reduce yearly consumer drug expenditure by 1.6 percent.

Citation

Atal, Juan Pablo, José Ignacio Cuesta, Felipe González, and Cristóbal Otero. 2024. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets." American Economic Review, 114 (3): 615-44. DOI: 10.1257/aer.20211547

Additional Materials

JEL Classification

  • D22 Firm Behavior: Empirical Analysis
  • I18 Health: Government Policy; Regulation; Public Health
  • L32 Public Enterprises; Public-Private Enterprises
  • L65 Chemicals; Plastics; Rubber; Drugs; Biotechnology
  • O14 Industrialization; Manufacturing and Service Industries; Choice of Technology